Skip to main content

The independent source for health policy research, polling, and news.

Subscribe Follow Us Donate
  • Trump 2.0

    Trump 2.0

    • Agency Watch
    • State Watch
    • Medicaid Watch
    • Rural Health Payout
  • Public Health

    Public Health

    • Vaccines
    • CDC & Disease
    • Environmental Health
  • Audio Reports

    Audio Reports

    • What the Health?
    • Health Care Helpline
    • KFF Health News Minute
    • An Arm and a Leg
    • Health Hub
    • HealthQ
    • Silence in Sikeston
    • Epidemic
    • See All Audio
  • Special Reports

    Special Reports

    • Bill Of The Month
    • The Body Shops
    • Broken Rehab
    • Deadly Denials
    • Priced Out
    • Dead Zone
    • Diagnosis: Debt
    • Overpayment Outrage
    • Opioid Settlement Tracking
    • See All Special Reports
  • More Topics

    More Topics

    • Elections
    • Health Care Costs
    • Insurance
    • Prescription Drugs
    • Health Industry
    • Immigration
    • Reproductive Health
    • Technology
    • Rural Health
    • Race and Health
    • Aging
    • Mental Health
    • Affordable Care Act
    • Medicare
    • Medicaid
    • Children’s Health

  • High Postcancer Medical Bills
  • Federal Workers’ Health Data
  • Cyberattacks on Hospitals
  • ‘Cheap’ Insurance

Morning Briefing

Summaries of health policy coverage from major news organizations

  • Email

Monday, Jan 25 2021

Full Issue

CDC Says Anaphylaxis After Covid Vaccines Is 'Rare Event'

Data shows the rates for severe allergic reactions to the Moderna vaccine are low, the CDC said in a new report. That's consistent with their findings for the Pfizer-BioNTech shot.

Stat: CDC Reports Rare Allergic Reactions To Moderna's Covid-19 Vaccine 

The Moderna Covid-19 vaccine, like the one made by Pfizer and BioNTech, appears to induce rare anaphylactic reactions in a small number of people who receive the vaccine, new data from the Centers for Disease Control and Prevention suggest. As of Jan. 19, there have been 15 confirmed cases of anaphylaxis after receipt of Moderna’s vaccine and 45 confirmed cases of anaphylaxis after receipt of the Pfizer vaccine, the CDC said in a statement to STAT. (Branswell, 1/22)

Los Angeles Times: Severe Allergic Reactions To Moderna Vaccine Are Rare, CDC Says

The COVID-19 vaccine developed by Moderna and the National Institutes of Health caused very few cases of severe allergic reactions during the first three weeks of its administration across the country, according to a new report from the Centers for Disease Control and Prevention. Among 4,041,396 doses given over 21 days, a total of 10 cases of anaphylaxis were confirmed by CDC investigators. Another four cases of possible anaphylaxis are still being investigated. No deaths have been tied to the vaccine. “Based on this early monitoring, anaphylaxis after receipt of Moderna COVID-19 vaccine appears to be a rare event,” the researchers wrote Friday in the CDC’s Morbidity and Mortality Weekly Report. (Kaplan, 1/24)

The Wall Street Journal: California Authorities Probe Death Of Person Who Received Covid-19 Vaccine Hours Earlier

California authorities are investigating the case of a person who died several hours after receiving a Covid-19 vaccine last week. The Placer County Sheriff’s Office and Placer County Public Health department were recently notified of the vaccination and death, which happened Thursday, according to a statement posted to Facebook by the sheriff’s office. It isn’t clear which vaccine the person received or whether the vaccine played a role in their death. (Toy, 1/24)

More on vaccine development —

Southern California News Group: Dozens Of New COVID Vaccines Working Their Way To Public

Move over, Pfizer and Moderna. You won’t be the only games in town too much longer. COVID-19 has existed for barely more than a year, but 64 vaccines are in clinical development and another 173 in preclinical development worldwide nonetheless, according to the World Health Organization. Dozens of hopefuls are in clinical trials in the U.S., including several by California researchers. But the two inching closest to the finish line here — by Oxford-AstraZeneca and Johnson & Johnson — could win emergency use authorization from the U.S. Food and Drug Administration as soon as this spring, which would instantly increase supply and deliver a much-needed jolt to the nation’s maddeningly sluggish mass vaccination campaign. (Sforza, 1/24)

KHN: Vaccine Ramp-Up Squeezes Covid Testing And Tracing

California Gov. Gavin Newsom, under growing pressure to jump-start a faltering covid-19 vaccine rollout, jetted to Los Angeles on Jan. 15 to unveil a massive new vaccination site at Dodger Stadium that is expected eventually to inoculate 12,000 people a day. The city-run venue had been the biggest covid testing site in the U.S., administering over 1 million tests in its nearly eight months of operation — and over 10,000 a day during the recent surge. Its redeployment to the cause of vaccination, Newsom declared, provides “an extraordinary world-class site for a world-class logistics operation.” (Wolfson, 1/25)

This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
Newsletter icon

Sign Up For Our Newsletter

Stay informed by signing up for the Morning Briefing and other emails:

Recent Morning Briefings

  • Today, April 22
  • Tuesday, April 21
  • Monday, April 20
  • Friday, April 17
  • Thursday, April 16
  • Wednesday, April 15
More Morning Briefings
RSS Feeds
  • Podcasts
  • Special Reports
  • Morning Briefing
  • About Us
  • Donate
  • Staff
  • Republish Our Content
  • Contact Us

Follow Us

  • Instagram
  • YouTube
  • LinkedIn
  • Facebook
  • X
  • Bluesky
  • TikTok
  • RSS

Sign up for emails

Join our email list for regular updates based on your personal preferences.

Sign up
  • Editorial Policy
  • Privacy Policy

© 2026 KFF